No Data
The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?
Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.
Hong Kong stocks fluctuate | IMMUNEONCO-B (01541) surged over 15% in the afternoon, with data from the clinical trial of combined chemotherapy IMM2510 expected to be released in the second half of the year.
IMMUNEONCO-B (01541) rose over 15% in the afternoon, as of the time of writing, it is up 14.4% at 5.56 HKD, with a trading volume of 91.407 million HKD.
China Merchants Bank International: Maintains 3SBIO 'Buy' rating as early clinical data for PD-1/VEGF dual antibody is announced.
CMB International released a Research Report stating that it maintains a "Buy" rating for 3SBIO (01530) with a Target Price of HKD 9.91, believing the Company Valuation is attractive, profit growth is stable, and the innovation pipeline has potential for expansion abroad. It is expected that the company's revenue and Net income will grow by 12% and 13% year-on-year respectively by 2025. Based on a 9-year DCF model, a Target Price of HKD 9.91 is given (WACC: 12.20%, perpetual growth rate: 2.0%), corresponding to a PE of 10.0 times for 2025. CMB International's main points are as follows: 707 (PD-1/VEGF) demonstrates excellent potential.
Express News | Instil Bio Inc - Plans U.S. Trial of Syn-2510/Imm2510 in 2H 2025
Express News | Instil Bio Inc - Initial Clinical Data From 1L Advanced Nsclc Trial in China Expected 2H 2025
Express News | Instil Bio Announces Clinical Progress in China for Imm2510/Syn-2510, a Clinical-Stage Pd-L1Xvegf Bispecific Antibody
